EASL Studio Podcast S9 E12: Collaborating across disciplines to find the best solution for people living with PBC

EASL Studio Podcast S9 E11: What Can Be Done to Safeguard Young Adults from SLD?

EASL Studio Podcast S9 E10: Decoding AASLD The Liver Meeting: Trends Shaping Hepatology

EASL Studio Podcast: Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance

EASL Studio Podcast S9 E08: MASLD in Practice: Who to Treat, With What, and for How Long?

EASL Studio Podcast S9 E07: Behind the Decision: How Can You Maximize Your Chances of Publication in JHEP Reports?

EASL Studio Podcast S9 E06: Are we finally entering an era of effective treatment for PSC?

EASL Studio Podcast S9 E05: Does it really matter whether we call it ACLF or acute decompensation?

EASL Studio Podcast S9 E04: The Clinical Blind Spot: Are We Neglecting Alcohol?

EASL Studio Podcast S9 E03: Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?

EASL Studio Podcast S9 E02: What Matters Most? The questions every hepatologist should ask their patients

EASL Studio Podcast S9 E1: Treating PBC: Alkaline Phosphatase response or improvement in liver stiffness?

EASL Studio Podcast S8 E15: EASL CPGs on Vascular Liver Diseases: What’s New?

EASL Studio Podcast S8 E14: Steatotic Liver Disease Unpacked: Targeting Dynamic Risks

EASL Studio Podcast S8 E13: Artificial Intelligence: Is This the Beginning of the End of the Medical Profession as We Know It?

EASL Studio Podcast S8 E12: Rethinking Hepatitis B: Discussions with Patients – Adapting to Expanding Treatment Guidelines

EASL Studio Podcast S8 E11: Interprofessional Session: Implementing the New EASL MASLD Guidelines into Clinical Practice

EASL Studio Podcast: Landmark studies at EASL Congress 2025

EASL Studio Podcast: Screening strategies for liver fibrosis

EASL/CIRSE Studio Podcast: Interventional radiology in hepatology: Building bridges to optimise care

EASL Studio Podcast: Beyond the myths: Alcohol harm and policy action

EASL Studio Podcast S8 E10: Endoscopic Management of Variceal Bleeding: Outdated or Evolving Beyond Tradition?

EASL Studio Podcasts S8 E9: JHEP Live: JHEP at 40: What to Expect Next?

EASL Studio Podcast S8 E8: Rare Liver Malignancies: Small Numbers, Big Questions

EASL Studio Podcast S8 E7: From Evidence to Action: Reducing Alcohol-Related Harm

EASL Studio Podcast S8 E6: Understanding Sex Disparities in MASLD

EASL Studio Podcast S8 E5: Lessons from Your PET: Understanding and Evaluating Treatment for Wilson’s Disease

EASL Studio Podcast S8 E4: Liver Cancer Care in 2025: Progress, Hope, and What Lies Ahead

EASL Studio Podcast S8 E3: YI Choice: From Idea to Abstract to Publication: Navigating Your Research Journey

EASL Studio Podcast S8 E2: JHEP Live – EASL CPGs on Hepatocellular Carcinoma: What’s New and How Will Practice Change?

EASL Studio Podcast S8 E1: 2025 Update on Steatotic Liver Disease: Rethinking Standard of Care

EASL Studio Podcast S7 E10: The liver as a master regulator of ageing, health, and longevity

EASL Studio Podcast S7 E9: TIPS: How far can we go?

EASL Studio Podcast S7 E8: Sarcopenia: Converting research findings into clinical practice - Are we doing enough?

EASL Studio Podcast S7 E7: Alcohol, cardiometabolic risks factors, and steatotic liver disease – From stigma to breakthrough therapies

EASL Studio Podcast S7 E6: What’s hot and not in liver transplantation: EASL CPG 2024 update

EASL Studio Podcast S7 E5: Why does WHO engagement with Steatotic Liver Disease matter?

EASL Studio Podcast S7 E4: Is it time to abandon the use of ultrasound for HCC surveillance in MASLD?

EASL Studio Podcast S7 E3: The changing face of Steatotic Liver Disease: Navigating new opportunities and emerging challenges

EASL Studio Podcast S7 E2: What does the future management of PBC look like?

EASL Studio Podcast S7 E1: Are we relearning how to manage renal dysfunction in cirrhosis?

EASL Studio Podcast: Landmark studies at the EASL Congress 2024

EASL Studio Podcast: Arrivederci Milano, hallo Amsterdam!

EASL Studio Podcast: Exploring new frontiers: The AI liver taskforce initiative

EASL Studio Podcast: SLD nomenclature: Need for refinement?

EASL Studio Podcast: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and prevention

EASL Studio Podcast: Unlocking breakthroughs: Pioneering drug development for ALD and MetALD

EASL Studio Podcast: Education at the heart of EASL’s mission

EASL Studio Podcast: New therapeutic options and remaining challenges in PBC

EASL Studio Podcast: Breaking boundaries: Innovating the future of hepatitis B and D treatment together

EASL Studio Podcast: Buongiorno Milano: What not to miss during EASL Congress

EASL Studio Podcast: Advances in systemic treatments in liver cancer

EASL Studio Podcast: MASLD anno 2024: A rapidly changing landscape

EASL Studio Podcast S6 E15: What‘s hot in viral hepatitis in 2024?

EASL Studio Podcast S6 E14: Endohepatology: The endoscopic liver gold rush

EASL Studio Podcast S6 E13: Resmetirom: First approved drug for MASH, for whom and for how long?

EASL Studio Podcast S6 E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?

EASL Studio Podcast S6 E10: YI Choice: Citizen science: Societal engagement in hepatology

EASL Studio Podcast S6 E9: Therapy hierarchy in HCC: A new kid on the block

EASL Studio Podcast S6 E8: Is there a role for measuring blood ammonia in patients with cirrhosis?

EASL Studio Podcast S6 E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study

EASL Studio Podcast S6 E6: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

EASL Studio Podcast S6 E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?

EASL Studio Podcast S6 E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond

EASL Studio Podcast S6 E3: How to stop recurrent bleeding due to small-intestinal angiodysplasia?

EASL Studio Podcast S6 E2: Why do we need HBV functional cure?

EASL Studio Podcast S6 E1: Do we solve MASLD by treating obesity?

EASL Studio Podcast S5 E15: EASL Studio’s holiday reflection: A look back to leap forward

EASL Studio Podcast S5 E14: Hepatic encephalopathy: Underdiagnosed and underestimated

EASL Studio Podcast S5 E13: Basics in decision-making for liver cancer treatment

EASL Studio Podcast S5 E12: PSC and AIH overlap syndrome: does it actually exist?

EASL Studio Podcast S5 E11: The window hypothesis again, or just a closed window?

EASL Studio Podcast S5 E10: Why should diabetologists care about the liver?

EASL Studio Podcast S5 E9: Alcohol and the new nomenclature – A game-changer?

EASL Studio Podcast S5 E8: JHEP Live: Hepatitis delta’s latest debate: Updates straight from EASL’s slate

EASL Studio Podcast S5 E7: Why bother with diet and exercise when an injection will suffice?

EASL Studio Podcast S5 E6: YI Choice: When stars fade: The untold story of burnout in academia

EASL Studio Podcast S5 E5: JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approach

EASL Studio Podcast S5 E4: PBC: The itch we need to scratch

EASL Studio Podcast S5 Special Edition: Highlights from the EASL SLD Summit 2023

EASL Studio Podcast S5 E3: Zoonotic Hepatitis E – What’s hot in 2023?

EASL Studio Podcast S5 E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways

EASL Studio Podcast S5 E1: What is really new in the EASL CPG on ACLF?

EASL Studio Podcast: Highlights of liver cancer research at EASL Congress 2023

EASL Studio Podcast: EASL Congress 2023: Back to the future

EASL Studio Podcast: Practice changing highlights from EASL Congress 2023

EASL Studio Podcast: United we stand: Global societies collaborating to beat liver disease

EASL Studio Podcast: Steatotic liver disease global consensus to change nomenclature

EASL Studio Podcast: The battle to reduce alcohol harms… EASL’s new policy

EASL Studio Podcast S4 E23: The conundrum of NASH: The growing global disease burden with low disease awareness

EASL Studio Podcast S4 E22: JHEP Live: New and promising drugs for NASH on the horizon

EASL Studio Podcast S4 E21: Why you should stop smoking if you love your liver

EASL Studio Podcast S4 E20: COST Actions: Opportunities for pan-European collaborations in liver diseases

EASL Studio Podcast S4 Special Edition: Promoting Liver Health: An urgent call for action at WHO

EASL Studio Podcast S4 E19: HDV: The devil becomes treatable

EASL Studio Podcast S4 E18: Liver nurses in Europe: Are there enough and can they do more?

EASL Studio Podcast S4 E17: Albumin in cirrhosis: For all, for some, for none

EASL Studio Podcast S4 E16: Highlights from the EASL Liver Cancer Summit 2023

EASL Studio Podcast S4 E15: Diagnostic and therapeutic challenges in Wilson’s disease

EASL Studio Podcast S4 Special Edition: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance

EASL Studio Podcast S4 E14: EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failure

EASL Studio Podcast S4 E13: JHEP Live: Liver transplantation for alcohol-related hepatitis

EASL Studio Podcast S4 E12: NAFLD and NASH – moving beyond the liver biopsy – where are we now?

EASL Studio Podcast S4 E11: YI Choice: Gene therapy for liver disease — RNA interference and beyond

EASL Studio Podcast S4 E10: Ascites: New solution for an old problem?

EASL Studio Podcast S4 E9: YI Choice: Gender equality in academics — reducing the gap

EASL Studio Podcast S4 E8: Alcohol and food policies

EASL Studio Podcast S4 E7: Genetics in adult liver disease – missed opportunities?

EASL Studio Podcast S4 E6: Regenerating the liver graft with a machine?

EASL Studio Podcast S4 E5: AI for Dummies

EASL Studio Podcast S4 E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?

EASL Studio Podcast S4 E3: A 360 approach to beat alcohol-related liver disease

EASL Studio Podcast S4 E2: YI Choice: How to build consortia and registries

EASL Studio Podcast S4 E1: Hepatitis B elimination: How far behind are we and what do we need to change to achieve it?

EASL Studio Podcast S3 E16: Liver cancer in 2022: Wrap-up & outlook

EASL Studio Podcast S3 E15: Chronic portal vein thrombosis: Anticoagulation and interventional radiology for all patients?

EASL Studio Podcast S3 E14: The future of hepatology

EASL Studio Podcast S3 E13: Next-generation metrics for science beyond journal impact factor and citations: The role of social media

EASL Studio Podcast S3 E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

EASL Studio Podcast S3 E11: Regenerative Hepatology: From stem cells to tissue engineering

EASL Studio Podcast S3 E10: Cholestatic pruritus: Can the itch be ditched?

EASL Studio Podcast S3 E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all?

EASL Studio Podcast S3 E8: Transplanting patients with cancer – Is there a limit?

EASL Studio Podcast S3 Special Edition: Ending fatty liver disease as a public health threat

EASL Studio Podcast S3 E7: Bugs and the liver — The role of the gut microbiome in liver diseases

EASL Studio Podcast S3 E6: How to improve end-of-life care in liver disease?

EASL Studio Podcast S3 E5: JHEP Live: Stigma and alcohol

EASL Studio Podcast S3 E4: Special Edition: Highlights of EASL NAFLD Summit 2022

EASL Studio Podcasts S3 E3: Primary biliary cholangitis: a look at the future landscape of therapy for patients

EASL Studio Podcasts S3 E2: Liver transplantation for ACLF: Opportunities, challenges and pitfalls

EASL Studio Podcasts S3 E1: JHEP Live: Covid vaccination and associated autoimmune hepatitis

EASL Studio Podcast S2 E18: How can our response to the climate crisis transform and improve hepatology services?

EASL Studio Podcast S2 E17: EASL Haemochromatosis Guidelines 2022

EASL Studio Podcast S2 E16: The NAFLD pandemic

EASL Studio Podcast S2 E15: JHEP Live on the best animal model for HCC – Lost in translation?

EASL Studio Podcast S2 E14: Elastography – The new non-invasive gold standard in portal hypertension?

EASL Studio Podcast Special Edition: Unexplained acute hepatitis in children

EASL Studio Podcast S2 E13: Digital Pathology

EASL Studio Podcast S2 E12: Nurse and AHP Focus: Sustainable hepatology – Insights in nursing initiatives

EASL Studio Podcast S2 E11: JHEP Live: Stop Nuc in HBeAg negative patients

EASL Studio Podcast S2 E10: LITMUS: Defining the colour of NAFLD

EASL Studio podcast S2 E9: YI Choice: Propelling liver cell biology into the third dimension

EASL Studio Podcast S2 E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

EASL Studio Podcast S2 E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathy

EASL Studio Podcast S2 E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?

EASL Studio Podcast S2 E5: New era for science dissemination: The role of social media

EASL Studio Podcast S2 E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?

EASL Studio Podcast S2E3: Interview with Stephan Urban - From bench to bedside: Process of developing the first HBV/HDV entry inhibitor

EASL Studio Podcast S2E1: New treatment options for hereditary cholestasis syndromes: A game-changer?

EASL Studio Podcast S6 E12: Do we care enough about the importance of DILI/DHILI ?